formoterol fumarate(redirected from Perforomist)
Also found in: Dictionary.
Pharmacologic class: Sympathomimetic; long-acting, selective beta2-adrenergic receptor agonist
Therapeutic class: Bronchodilator
Pregnancy risk category C
Stimulates intracellular adenylate cyclase, relaxing bronchial smooth muscle and inhibiting release of mediators of immediate hypersensitivity
Capsules for oral inhalation (used with Aerolizer inhaler): 12 mcg
Indications and dosages
➣ Long-term maintenance of asthma; prevention or long-term maintenance of bronchospasm in patients with chronic obstructive pulmonary disease
Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer q 12 hours
➣ Acute prevention of exercise-induced bronchospasm (on occasional, as-needed basis)
Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer at least 15 minutes before start of exercise. Wait 12 hours after initial dose before giving repeat dose.
• Hypersensitivity to drug or its components
Use cautiously in:
• acute asthma symptoms, deteriorating asthma, cardiovascular disorders, seizure disorders, thyrotoxicosis, diabetes, possible hypokalemia
• patients older than age 75
• pregnant or breastfeeding patients
• children younger than age 5.
• Be aware that drug is not intended for acute asthma attacks.
• Use capsules only with Aerolizer inhaler supplied.
• Keep capsules in blister until immediately before use.
☞ Make sure patient doesn't swallow capsules.
CNS: tremor, dizziness, insomnia, anxiety
CV: chest pain
EENT: sinusitis, pharyngitis, tonsillitis
GI: dry mouth
Metabolic: hypokalemia, hyperglycemia
Musculoskeletal: muscle cramps, back pain, leg cramps
Respiratory: bronchitis, chest infection, dyspnea, upper respiratory tract infection, increased sputum
Skin: pruritus, rash
Other: dysphonia, viral infection, fever
Drug-drug. Adrenergics: potentiation of formoterol's sympathomimetic effects
Beta-adrenergic blockers: partial or total inhibition of formoterol's effects
Cardiac glycosides, methylxanthines, potassium-wasting diuretics, steroids: potentiation of formoterol's hypokalemic effects, increased risk of arrhythmias
Disopyramide, MAO inhibitors, quinidine, phenothiazines, procainamide, tricyclic antidepressants: prolonged QTc interval, increased risk of ventricular arrhythmias
Halogenated hydrocarbon anesthetics: increased risk of arrhythmias
Levodopa, levothyroxine, oxytocin: impaired cardiac tolerance of formoterol
Drug-diagnostic tests. Blood glucose: increased level
Potassium: decreased level
Drug-behaviors. Alcohol use: impaired cardiac tolerance of formoterol
• Monitor pulmonary function test results.
• Monitor potassium and glucose levels.
• Teach patient how to use capsules and Aerolizer inhaler provided.
• Instruct patient to keep capsules in blisters until immediately before use.
• Caution patient not to swallow capsules.
• Tell patient not to use drug for acute asthma attacks.
☞ Instruct patient to contact prescriber immediately if difficulty in breathing persists after using drug or if condition worsens.
• Caution patient to take drug exactly as prescribed and not to stop therapy even if he feels better.
• Tell patient to consult prescriber if he has been taking inhaled, short-acting drugs on a regular basis.
• Advise female patient to tell prescriber if she is pregnant or breastfeeding or if she plans to become pregnant.
• Caution patient to avoid alcohol during therapy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.